Point72 Asset Management
IOVA icon

Point72 Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Point72 Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200,000
Closed -$1.48M – 2277
2024
Q4 		$1.48M Buy
+200,000
New +$1.85M ﹤0.01% 1355
2020
Q3 		– Sell
-300,000
Closed -$8.23M – 1002
2020
Q2 		$8.23M Sell
300,000
-60,000
-17% -$1.97M 0.05% 382
2020
Q1 		$10.8M Buy
+360,000
New +$9.54M 0.09% 298

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Point72 Asset Management's IOVA Position: Q4 2023 in Review

Point72 Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2023, closing a stake of 1,412,550 shares — an estimated $6.43M sold.

Point72 Asset Management first reported a position in IOVA in Q2 2019 and held it in 9 quarters. The position peaked at $91.8M in Q1 2020. 236 funds tracked by Wall St. Rank hold IOVA as of Q4 2023.

  • Point72 Asset Management reported no remaining Iovance Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Point72 Asset Management sold 1,412,550 Iovance Biotherapeutics shares in Q4 2023, an estimated $6.43M.
  • Point72 Asset Management first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 9 quarters.
  • Point72 Asset Management's Iovance Biotherapeutics position peaked at $91.8M in Q1 2020.
  • 236 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2023.

Based on Point72 Asset Management's 13F filing for Q4 2023, filed 14 Feb 2024.